Common use of Charitable Foundation Clause in Contracts

Charitable Foundation. AlCana is currently concluding an agreement with a charitable foundation (“Foundation”) covering a research and development program. The name of the Foundation will be disclosed in the detailed agreement. The planned research is directed at development of potential therapeutics for the treatment of a specific chronic and currently untreatable disease (“Foundation Disease”) [Redacted – Research Field]. The research program will include studies involving potential RNAi therapeutics. Tekmira agrees that AlCana will undertake this program under the following conditions: i. Any Intellectual Property that is generated in the collaboration will be called “Foundation IP” ii. All Foundation IP will be held and prosecuted by AlCana iii. AlCana will grant to Tekmira an exclusive license to the Foundation IP in the Field of Use, subject to the rights granted to the Foundation below iv. AlCana will grant to the Foundation exclusive rights to the Foundation IP related specifically to the Foundation Disease The Foundation will pay to AlCana a [Redacted – percentage]% royalty (less offsets) on Net Sales. AlCana will pass through [Redacted – percentage]% of any royalty it obtains from the Foundation to Tekmira Alnylam Identified Sublicensees: AlCana Technologies, Inc. Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Genzyme Corporation Monsanto Company Novartis Institutes for BioMedical Research, Inc. Regulus Therapeutics Inc. (formerly Regulus Therapeutics LLC)

Charitable Foundation. AlCana is currently concluding an agreement with a charitable foundation (“Foundation”) covering a research and development program. The name of the Foundation will be disclosed in the detailed agreement. The planned research is directed at development of potential therapeutics for the treatment of a specific chronic and currently untreatable disease (“Foundation Disease”) [Redacted – Research Field]. The research program will include studies involving potential RNAi therapeutics. Tekmira agrees that AlCana will undertake this program under the following conditions: i. Any Intellectual Property that is generated in the collaboration will be called “Foundation IP” ii. All Foundation IP will be held and prosecuted by AlCana iii. AlCana will grant to Tekmira an exclusive license to the Foundation IP in the Field of Use, subject to the rights granted to the Foundation below iv. AlCana will grant to the Foundation exclusive rights to the Foundation IP related specifically to the Foundation Disease The Foundation will pay to AlCana a [Redacted – percentage]% royalty (less offsets) on Net Sales. AlCana will pass through [Redacted – percentage]% of any royalty it obtains from the Foundation to Tekmira EXHIBIT B - 33 - Alnylam Identified Sublicensees: AlCana Technologies, Inc. Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Genzyme Corporation Monsanto Company Novartis Institutes for BioMedical Research, Inc. Regulus Therapeutics Inc. (formerly Regulus Therapeutics LLC)

Charitable Foundation. AlCana is currently concluding an agreement with a charitable foundation (“Foundation”) covering a research and development program. The name of the Foundation will be disclosed in the detailed agreement. The planned research is directed at development of potential therapeutics for the treatment of a specific chronic and currently untreatable disease (“Foundation Disease”) [Redacted – Research Field**]. The research program will include studies involving potential RNAi therapeutics. Tekmira agrees that AlCana will undertake this program under the following conditions: i. Any Intellectual Property that is generated in the collaboration will be called “Foundation IP” ii. All Foundation IP will be held and prosecuted by AlCana iii. AlCana will grant to Tekmira an exclusive license to the Foundation IP in the Field of Use, subject to the rights granted to the Foundation below iv. AlCana will grant to the Foundation exclusive rights to the Foundation IP related specifically to the Foundation Disease The Foundation will pay to AlCana a [Redacted – percentage]% **]% royalty (less offsets) on Net Sales. AlCana will pass through [Redacted – percentage]% **]% of any royalty it obtains from the Foundation to Tekmira [**] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Alnylam Identified Sublicensees: AlCana Technologies, Inc. Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Genzyme Corporation Monsanto Company Novartis Institutes for BioMedical Research, Inc. Regulus Therapeutics Inc. (formerly Regulus Therapeutics LLC)

Charitable Foundation. AlCana is currently concluding an agreement with a charitable foundation (“Foundation”) covering a research and development program. The name of the Foundation will be disclosed in the detailed agreement. The planned research is directed at development of potential therapeutics for the treatment of a specific chronic and currently untreatable disease (“Foundation Disease”) [Redacted – Research Field**]. The research program will include studies involving potential RNAi therapeutics. Tekmira agrees that AlCana will undertake this program under the following conditions: i. Any Intellectual Property that is generated in the collaboration will be called “Foundation IP” ii. All Foundation IP will be held and prosecuted by AlCana iii. AlCana will grant to Tekmira an exclusive license to the Foundation IP in the Field of Use, subject to the rights granted to the Foundation below iv. AlCana will grant to the Foundation exclusive rights to the Foundation IP related specifically to the Foundation Disease The Foundation will pay to AlCana a [Redacted – percentage]% **]% royalty (less offsets) on Net Sales. AlCana will pass through [Redacted – percentage]% **]% of any royalty it obtains from the Foundation to Tekmira Alnylam Identified Sublicensees: AlCana Technologies, Inc. Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Genzyme Corporation Monsanto Company Novartis Institutes for BioMedical Research, Inc. Regulus Therapeutics Inc. (formerly Regulus Therapeutics LLC)